Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rare Disease Specialist Ultragenyx Takes $45MM Series A Round

This article was originally published in The Pink Sheet Daily

Executive Summary

Led by a BioMarin veteran, the year-old startup has already licensed five compounds, and is preparing to take one into the clinic.
Advertisement

Related Content

Ultragenyx Plans Five Clinical Trials For 2014
Ultragenyx Takes On Rare Childhood Disease With In-licensing Deal
Ultragenyx Raises $75 Million Series B, Prepares For A 2014 IPO
Ultragenyx Pharmaceutical LLC
Rare Disease Research: Where Compassion Meets Commerce
Pfizer Adds To Specialty Care Division With Purchase Of FoldRx
Pfizer Adds To Specialty Care Division With Purchase Of FoldRx

Topics

Advertisement
UsernamePublicRestriction

Register

PS072394

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel